Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "MIA"

455 News Found

Lilly opens biotech in San Diego
Startup | September 29, 2025

Lilly opens biotech in San Diego

82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines


Roche secures CE mark for Accu-Chek SmartGuide CGM with mySugr app integration
News | September 19, 2025

Roche secures CE mark for Accu-Chek SmartGuide CGM with mySugr app integration

This predictive technology empowers people with diabetes to take preventive action before complications arise


FDA approves Lupin’s Lenalidomide capsules
Drug Approval | September 17, 2025

FDA approves Lupin’s Lenalidomide capsules

Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma


GAIASO appoints Dr. Tracey Brown as CEO
People | September 16, 2025

GAIASO appoints Dr. Tracey Brown as CEO

Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,


MoS Health Patel inaugurates National Virus Research & Diagnostic Laboratory Conclave 2025
News | September 16, 2025

MoS Health Patel inaugurates National Virus Research & Diagnostic Laboratory Conclave 2025

Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem


Granules India and NIPER S.A.S Nagar launch CoE for sustainable pharma innovation
Sustainability | September 05, 2025

Granules India and NIPER S.A.S Nagar launch CoE for sustainable pharma innovation

It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks


AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension
Clinical Trials | September 05, 2025

AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension

The medicine was well tolerated, with no unexpected safety issue


Merck’s oral PCSK9 inhibitor Enlicitide shows promising results in phase 3 CORALreef lipids study
Clinical Trials | September 04, 2025

Merck’s oral PCSK9 inhibitor Enlicitide shows promising results in phase 3 CORALreef lipids study

Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol